Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Conba Pharmaceutical CoSHSE:600572 +1.80%74 ROC (Joel Greenblatt) % is 24.18% as of Jun. 2026, which is 5% below its 10-year median of 25.51. GuruFocus rates SHSE:600572 with a GF Score™ of 74/100 and a GF Value™ of ¥5.41 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 980 Drug Manufacturers companies, Zhejiang Conba Pharmaceutical Co ranks better than 62.35% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Zhejiang Conba Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 24.18%.
The historical rank and industry rank for Zhejiang Conba Pharmaceutical Co's ROC (Joel Greenblatt) % or its related term are showing as below:
SHSE:600572'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 3.2 Med: 25.51 Max: 72.19
Current: 19.22
During the past 13 years, Zhejiang Conba Pharmaceutical Co's highest ROC (Joel Greenblatt) % was 72.19%. The lowest was 3.20%. And the median was 25.51%.
SHSE:600572's ROC (Joel Greenblatt) % is ranked better than 62.35% of 980
companies
in the Drug Manufacturers industry
Industry Median: 10.885
vs SHSE:600572: 19.22
Zhejiang Conba Pharmaceutical Co (SHSE:600572) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Conba Pharmaceutical Co ROC (Joel Greenblatt) % Chart
SHSE:600572 vs ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Conba Pharmaceutical Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Conba Pharmaceutical Co ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Conba Pharmaceutical Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Zhejiang Conba Pharmaceutical Co's ROC (Joel Greenblatt) % falls into.
Zhejiang Conba Pharmaceutical Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 24.18% mean?
Zhejiang Conba Pharmaceutical Co (SHSE:600572) has a ROC (Joel Greenblatt) % of 24.18% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. This is near median its historical median of 25.51. Over the past decade, Zhejiang Conba Pharmaceutical Co's ROC (Joel Greenblatt) % has ranged from 3.20 to 72.19. According to the industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #369 out of 980 companies in the Drug Manufacturers industry, placing it in the top 37.7%.
Is Zhejiang Conba Pharmaceutical Co's ROC (Joel Greenblatt) % too high?
Zhejiang Conba Pharmaceutical Co's current ROC (Joel Greenblatt) % of 24.18% is near median its 10-year median of 25.51. Over the past 10 years, this metric has ranged from a low of 3.20 to a high of 72.19. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 10.89. Zhejiang Conba Pharmaceutical Co's value of 24.18% is 122.1% above this industry median. Based on the distribution chart, Zhejiang Conba Pharmaceutical Co ranks #369 out of 980 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zhejiang Conba Pharmaceutical Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Conba Pharmaceutical Co's ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #369 out of 980 companies for ROC (Joel Greenblatt) %. This puts Zhejiang Conba Pharmaceutical Co in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 10.89. Zhejiang Conba Pharmaceutical Co's value of 24.18% is 122.1% above this benchmark. Historically, Zhejiang Conba Pharmaceutical Co's own ROC (Joel Greenblatt) % has ranged from 3.20 to 72.19 over the past decade. While the company's 10-year median is 25.51 vs. the industry median of 10.89, Zhejiang Conba Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 10.89, based on 980 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Conba Pharmaceutical Co's current ROC (Joel Greenblatt) % of 24.18% is 122.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 10.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Conba Pharmaceutical Co's current ROC (Joel Greenblatt) % is 24.18%, which is near median its own 10-year median of 25.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Conba Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co (SHSE:600572) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.41, compared to a current price of ¥4.52 — trading 16.5% below its estimated fair value. The current ROC (Joel Greenblatt) % is 24.18%, which is near median its 10-year median of 25.51 and 122.1% above the Drug Manufacturers industry median of 10.89. Zhejiang Conba Pharmaceutical Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Zhejiang Conba Pharmaceutical Co (SHSE:600572), the current ROC (Joel Greenblatt) % is 24.18% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Conba Pharmaceutical Co (SHSE:600572) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥4.52 is trading 16.5% below its estimated GF Value™ of ¥5.41.
GuruFocus considers Zhejiang Conba Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600572:
ROC (Joel Greenblatt) %: 24.18% (near median its 10-year median of 25.51)
GF Value™: ¥5.41 vs. price of ¥4.52 (16.5% below fair value)
Industry Position: 122.1% above the Drug Manufacturers median (#369 of 980)
No single metric tells the full story. See the SHSE:600572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.
74GF Score
Get the complete analysis for SHSE:600572
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600572 has been successfully added to your 
